Efficacy and Safety of Linagliptin in General Surgical Patients with Type 2 Diabetes: Linagliptin Surgery Trial

被引：0
|
作者：
Vellanki, Priyathama
Alexanian, Sara
Baldwin, David
Rasouli, Neda
Anzola, Isabel A.
Ramos, Clementina
Urrutia, Maria A.
Jones, Jocelyn
Modzelewski, Katherine
Ensminger, Elizabeth
Bakhtiari, Hoda F.
Pasquel, Francisco
Fayfman, Maya
Haw, Sonya
Peng, Limin
Umpierrez, Guillermo E.
机构：
来源：
DIABETES | 2017年 / 66卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1254-P
引用
收藏
页码：A336 / A336
页数：1
相关论文
共 50 条
  • [1] Glycaemic efficacy and safety of linagliptin compared to basal bolus insulin regimen in non-cardiac surgical patients with type 2 diabetes: Linagliptin-Surgery trial
    Umpierrez, G.
    Vellanki, P.
    Rasouli, N.
    Baldwin, D.
    Alexanian, S.
    Anzola, I.
    Urrutia, M.
    Gomez, P.
    Cardona, S.
    Wang, H.
    Pasquel, F.
    DIABETOLOGIA, 2018, 61 : S377 - S378
  • [2] Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients with Severe Renal Impairment
    Sloan, Lance
    Newman, Jennifer
    Sauce, Christophe
    Von Eynatten, Maximilian
    Patel, Sanjay
    Woerle, Hans J.
    DIABETES, 2011, 60 : A114 - A114
  • [3] Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
    Guedes, Erika Paniago
    Hohl, Alexandre
    de Melo, Thais Gomes
    Lauand, Felipe
    DIABETOLOGY & METABOLIC SYNDROME, 2013, 5
  • [4] Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes and Poor Glycemic Control
    Del Prato, Stefano
    Taskinen, Marja-Riitta
    Owens, David
    Von Eynatten, Maximillian
    Emser, Angela
    Patel, Sanjay
    Woerle, Hans J.
    DIABETES, 2011, 60 : A293 - A293
  • [5] Efficacy and Safety of Linagliptin in Elderly Patients (≥ 70 Years) With Type 2 Diabetes
    Barnett, Anthony
    Huisman, Holger
    Jones, Russell
    Von Eynatten, Maximilian
    Patel, Sanjay
    Woerle, Hans-Juergen
    DIABETES, 2012, 61 : A260 - A261
  • [6] The safety and efficacy of Linagliptin in patients with type 2 diabetes with severe renal impairment
    Sloan, L.
    Newman, J.
    Sauce, C.
    von Eynatten, M.
    Patel, S.
    Woerle, H. J.
    Katsadze, V.
    DIABETES & METABOLISM, 2012, 38 : A102 - A103
  • [7] Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
    Erika Paniago Guedes
    Alexandre Hohl
    Thais Gomes de Melo
    Felipe Lauand
    Diabetology & Metabolic Syndrome, 5
  • [8] Pharmacology, Efficacy, and Safety of Linagliptin for the Treatment of Type 2 Diabetes Mellitus
    Neumiller, Joshua J.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (03) : 358 - 367
  • [9] Efficacy and Safety of Linagliptin as Add-On Therapy to Basal Insulin in Patients With Type 2 Diabetes
    Yki-Jarvinen, Hannele
    Duran-Garcia, Santiago
    Pinnetti, Sabine
    Bhattacharya, Sudipta
    Thiemann, Sandra
    Patel, Sanjay
    Woerle, Hans-Juergen
    DIABETES, 2012, 61 : A255 - A255
  • [10] Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors
    Gallwitz, Baptist
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2013, 4 (03) : 95 - 105
12345